OBSIDIAN THERAPEUTICS
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.
OBSIDIAN THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.obsidiantx.com
Total Employee:
51+
Status:
Active
Contact:
(781) 806-6245
Email Addresses:
[email protected]
Total Funding:
164.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Sitelinks Search Box Amazon
Similar Organizations
Ankyra
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments.
Aratana Therapeutics
Aratana Therapeutics develops innovative therapies for the animal health industry.
b.well Connected Health
b.well Connected Health provides an integrated solution for consumer engagement, holistic health management, and cost containment.
CareRx
CareRx is a provider of pharmacy services to seniors communities.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Cybin
Cybin is a life sciences company dedicated in advancing psychedelic therapeutics with the goal of transforming mental healthcare.
Denteric
Denteric is developing a vaccine based on research conducted at the University of Melbourne.
Dracen Pharmaceuticals
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
EIP Pharma
EIP Pharma Provides Healthcare Services.
Everest Medicines
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients.
Genomic Prediction
Genomic Prediction provides advanced genetic testing for IVF.
Icosavax
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Jaguar Health
Jaguar Health brings naturally derived important health solutions to all animals of the world, as proprietary.
Kalderos
Kalderos provides a SaaS based drug discount management solution, which identifies, checks, and resolves non-compliance.
Neukio Biotherapeutics
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.
Nivien Therapeutics
Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Sante Basque Developpement
Sante Basque Developpement is owns and operates mental health hospitals.
Syndesi Therapeutics
Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Tune Therapeutics
Tune Therapeutics is an epigenetic programming platform for the treatment of disease.
Vico Therapeutics
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
Westlake Therapeutics
The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.
Zucara Therapeutics
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.
Current Advisors List
Current Employees Featured
Founder
Investors List
The Column Group
The Column Group investment in Series B - Obsidian Therapeutics
Vertex Ventures HC
Vertex Ventures HC investment in Series B - Obsidian Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Obsidian Therapeutics
Amgen Ventures
Amgen Ventures investment in Series B - Obsidian Therapeutics
Bristol Myers Squibb
Bristol Myers Squibb investment in Series B - Obsidian Therapeutics
Logos Capital
Logos Capital investment in Series B - Obsidian Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Obsidian Therapeutics
Deep Track Capital
Deep Track Capital investment in Series B - Obsidian Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - Obsidian Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Obsidian Therapeutics
Official Site Inspections
http://www.obsidiantx.com Semrush global rank: 3.54 M Semrush visits lastest month: 4.15 K
- Host name: 2.198.243.35.bc.googleusercontent.com
- IP address: 35.243.198.2
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Obsidian Therapeutics"
obsidiantx.com Reviews | check if site is scam or legit| Scamadviser
Check obsidiantx.com with our free review tool and find out if obsidiantx.com is legit and reliable. Need advice? Report scams Check Scamadviser!See details»
Obsidiantx / Obsidian Therapeutics
. Check obsidiantx valuation, traffic estimations and owner info. Full analysis about obsidiantx.com.See details»
Sign in to your account
Web site created using create-react-appSee details»
OBX-115 | Investigational IL2-free TIL therapy with …
The Phase I FIH clinical trial for OBX-115 is currently recruiting patients with metastatic melanoma. Obsidian’s investigational lead program, OBX-115, is a novel, IL2-free, tumor-infiltrating lymphocyte (TIL) therapy engineered with regulated …See details»
Pioneering engineered cell and gene therapies | Obsidian Therapeutics
Our Name Obsidian is a volcanic glass that is used to make sharp and precise blades. Reflecting our namesake, our approach enables precise, patient-specific engineering of cell and gene therapies. …See details»
Whois obsidiantx.com
Domain: obsidiantx.com Registrar: GoDaddy.com, LLC Registered On: 2016-01-29 Expires On: 2026-01-29 Updated On: 2024-01-30 Status: clientDeleteProhibited clientRenewProhibited …See details»
Madan Jagasia - Obsidian Therapeutics | LinkedIn
Experienced Executive with a demonstrated history of working in the biotechnology… · Experience: Obsidian Therapeutics · Education: Vanderbilt University - Owen Graduate School of Management ...See details»
Obsidiantx Web Analysis - Obsidiantx.com
Obsidiantx.com is 9 years 3 months old. It is a domain having com extension. This website is estimated worth of $ 8.95 and have a daily income of around $ 0.15. As no active threats were …See details»
Obsidian Therapeutics to Present Preclinical Data from …
Nov 7, 2022 Preclinical data highlight numerous pipeline advancements: cytoTIL15™ cells armed with combination-cytokines modulate the tumor microenvironment (TME); spatial profiling of cytoTIL15 cells in PDX models …See details»
Obsidian Therapeutics | The next generation of …
Jun 2, 2025 Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.See details»
Obsidian Therapeutics Announces Leadership Transition …
Apr 18, 2019 “I am excited to be joining Obsidian Therapeutics at a pivotal time for the company,” said Dr. Wotton. “Mike and the team have built a world-class organization, executed on a strategic transformative partnership, and established …See details»
Obsidiantx.com Obsidian Therapeutics - HypeStat
Obsidiantx.com receives about 493 unique visitors per day, and it is ranked 3,281,505 in the world. obsidiantx.com uses Apache, Google Font API, Revslider ...See details»
Obsidian Therapeutics Announces Positive Interim Top-Line ... - CTMC
Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy Positive results …See details»
Obsidian Therapeutics to Present Clinical Data from OBX-115, its ...
Obsidian’s proprietary cytoDRiVE ® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in …See details»
Obsidian Therapeutics Announces Positive Clinical Data from
Jun 2, 2025 Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with …See details»
Obsidian Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Obsidian Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Ken Paxton launches investigation into Beto O’Rourke-led group …
1 day ago Ken Paxton launches investigation into Beto O’Rourke-led group over Texas quorum break The organization, Powered by People, has reportedly been helping support Texas state …See details»
Obsidian Therapeutics Announces Appointment of William Pao, …
CAMBRIDGE, Mass., June 4, 2024 – Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of …See details»
Obsidian Therapeutics to Present at the 43rd Annual J.P ... - BioSpace
Jan 7, 2025 Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with …See details»
Obsidian Therapeutics, Inc. (Obsidian Therapeutics, Inc.) - 药物管线_ …
Jun 15, 2025 Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is …See details»